YAP1 and melanoma: Previous study also points out that the increase of YAP1 in tumors with BRAFV600E mutation is a biomarker indicative of poor early response of patients (12), suggesting the potential of the expression of YAP1 in PLX 4032 drug-resistant melanoma as a novel research direction.